Treatment of pain in sickle-cell crisis

K. M. Foley, R. K. Portenoy, B. E. Rosenbloom, K. R. Tanaka, G. R. Buchanan, T. C. Griffin

Research output: Contribution to journalLetterpeer-review

1 Scopus citations

Abstract

To the Editor: Griffin et al. (March 17 issue)1 report decreased duration of severe pain in children and adolescents with sickle cell disease after treatment with high-dose methylprednisolone. There are serious deficiencies in the methods used in this clinical study that arouse both scientific and ethical concern. Simply stated, the authors confuse the duration of analgesic use with analgesia. They describe the main analgesic outcome measures as the number of morphine doses used, the need for continuous morphine infusions, and the duration of opioid therapy. Only the data on duration were statistically significant. Despite an abundant literature on pain measurement.

Original languageEnglish (US)
Pages (from-to)334-335
Number of pages2
JournalNew England Journal of Medicine
Volume331
Issue number5
DOIs
StatePublished - Aug 4 1994

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment of pain in sickle-cell crisis'. Together they form a unique fingerprint.

Cite this